This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mumps virus strain B level jeryl lynn live antigen is a vaccine used to prevent Mumps.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Mumps virus strain B level jeryl lynn live antigen
- DrugBank Accession Number
- DB10316
- Background
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Mumps virus vaccine live attenuated (Jeryl Lynn strain)
- Mumps Virus Vaccine Live, Jeryl Lynn Strain
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mumpsvax Powder, for solution 5000 unit / 0.5 mL Subcutaneous Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1969-12-31 2004-08-27 Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US 
M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 1971-04-21 Not applicable US M-M-R II VACCINE Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Rubella virus vaccine (1000 CCID50/0.5mL) Injection, powder, for solution Subcutaneous MSD PHARMA (SINGAPORE) PTE. LTD. 1988-06-24 Not applicable Singapore M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU 
M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 47QB6MX9KU
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Rheumatoid Arthritis, Juvenile 1 4 Completed Prevention Adverse Event Following Immunization / Measles / Mumps / Rubella 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Chickenpox / Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Encephalitis, Japanese B / Measles / Mumps / Rubella 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Measles / Mumps / Rubella 2 4 Completed Prevention Mumps 1 4 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Injection, powder, for solution Subcutaneous 1000 CCID50/0.5mL Injection, powder, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Powder, for solution Subcutaneous 5000 unit / 0.5 mL Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous 1000 TCID50/0.5ml Injection Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 1000 CCID50 Powder, for solution Intramuscular; Subcutaneous Powder, for solution Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Subcutaneous 3 log10 tcid50/0.5mL Injection Subcutaneous Solution Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at January 25, 2022 05:26